Genomics
Gene editing, CRISPR, synthetic biology, personalized medicine, longevity research
Genomics Concepts: The 2026 Editing Frontier
Base editing, prime editing, in-vivo CRISPR, epigenetic editing, precision longevity, and AI-designed gene editors
Genomics Concepts Sprint
Fast recall on base editing, prime editing, lonvo-z, LNP delivery, epigenetic editing, OSK reprogramming, and SCLR-seq
Genomics Companies & Labs
Match the editors, clinics, AI labs, and sequencing companies to their 2026 signatures
Genomics Speed Round
Quick-fire recall on the numbers and names of the 2026 gene-editing frontier
Genomics Timeline: The Editing Breakthroughs
Order the milestones from base editing's 2016 debut through Intellia's 2026 Phase 3 win
The Genomics Frontier: In Vivo, AI, and Reprogramming
The harder questions — safety signals, contested science, and the delivery bottleneck
Choosing a Gene-Editing Modality and Delivery Route in 2026
Make the modality, delivery, and clinical-strategy calls the 2026 evidence supports
Genomics Frontier Sprint
Advanced recall on trial toplines, safety signals, and the AI-designed biology numbers
GenScript Biotech Dossier: recent revenue
Estimate GenScript Biotech's revenue across the last 2 quarters. [Dossier may be stale — refresh recommended.]